Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Percutaneous hepatic perfusion with melphalan for unresectable colorectal liver metastases
NL-OMON28533Phase 2Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of melphalan in colorectal cancer (CRC), sponsored by Leiden University Medical Center. Primary endpoints: Overall response rate and Conversion to curative resection. Started Mar 2014; status: recruiting.
02
Drugs
melphalan
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NL-OMON28533.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28533.